Research programme: CB5064 analogues - CohBar
Alternative Names: CB5064 analogs - CohBarLatest Information Update: 28 Jun 2024
At a glance
- Originator Albert Einstein College of Medicine; University of California
- Developer CohBar
- Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Peptides
- Mechanism of Action Apelin receptor agonists; CXCR4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adult respiratory distress syndrome; Cancer
- No development reported SARS-CoV-2 acute respiratory disease; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in USA
- 28 Jul 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 01 Aug 2021 Preclinical trials in Cancer in USA